![]() |
市場調查報告書
商品編碼
2085498
內視鏡超音波市場:依產品、技術、應用和最終用戶分類-2026-2032年全球市場預測Endoscopy Ultrasound Market by Product, Technology, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,內視鏡超音波市場將成長至 20.8 億美元,複合年成長率為 8.01%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 12.1億美元 |
| 預計年份:2026年 | 13.1億美元 |
| 預測年份 2032 | 20.8億美元 |
| 複合年成長率 (%) | 8.01% |
超音波(通常稱為內視鏡超音波檢查或EUS)結合了高頻超音波影像和內視鏡視覺化技術,用於從消化道內部評估胃腸道和胰膽疾病。其臨床價值在斷層成像存在局限性的領域尤其明顯,例如胰腺病變的定性、粘膜下腫瘤的評估、膽管的評估、縱隔疾病的分期以及通過EUS引導下的細針穿刺或細針活體組織切片進行組織取樣。
EUS領域正從診斷視覺化轉向影像引導介入。線性迴聲內視鏡、改進的超音波處理系統、彈性成像、造影EUS和專用切片穿刺針能夠更可靠地評估病變並提高檢體採集的成功率,而介入性EUS正在拓展內鏡室在膽道引流、胰腺儲存處理以及特定患者的膽囊引流方面的作用。
人工智慧正透過影像解讀、工作流程最佳化、品管和決策支援等方式,開始影響超音波。在胃腸內視鏡領域,目前最成熟的商業性應用是人工智慧輔助大腸鏡息肉檢測,已獲得FDA批准和CE認證的電腦輔助檢測系統證明了將人工智慧融入實際內視鏡工作流程的可行性。另一方面,內視鏡超音波則走上了一條更為專業化的道路,因為影像品質、操作者技能、病變異質性以及缺乏標記資料集等因素,都給檢驗帶來了更高的挑戰。
由於亞太地區患者群體龐大、癌症篩檢能力不斷提高、三級醫療機構不斷擴建,以及中國、日本、韓國、印度、澳洲和東協等市場強勁的需求,該地區的超音波內視鏡(EUS)領域正經歷高速成長。日本和韓國擁有成熟的內視鏡體系,並在上消化道和胰膽手術方面擁有深厚的臨床經驗。同時,中國和印度正透過投資醫院基礎設施、培訓專家以及不斷擴大腫瘤轉診網路來擴大EUS的覆蓋範圍。在澳大利亞,先進的內視鏡中心集中分佈、高標準的臨床管治以及針對複雜胃腸道疾病的成熟治療方案,推動了EUS的普及應用。
東協地區的需求主要受私立醫院投資、醫療旅遊、胃腸道疾病診斷數量增加以及新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國專科網路擴張的推動。在海灣合作理事會(GCC)國家,隨著專科醫院的擴建、政府醫療現代化以及對微創癌症治療和肝膽疾病診療服務的需求,內視鏡超音波(EUS)的應用正在不斷推進。尤其是在沙烏地阿拉伯、阿拉伯聯合大公國、卡達和科威特,對三級醫療機構的投資正在支持先進的診斷和治療性內視鏡檢查。
在美國,EUS在重症病例中的應用主要由大學附屬醫院、門診內視鏡網路、胰臟癌計畫和先進的治療性內視鏡服務所主導。而在加拿大,重點則在於透過整個省級醫療保健系統和結構化的轉診途徑,以實證醫學為基礎進行推廣。墨西哥和巴西在拉丁美洲擁有最大的市場機會,這得益於私人醫療保健的擴張、專科轉診中心的增加以及主要大都會圈對先進診斷服務的需求。
行業領導者應優先考慮在真實臨床實踐中收集有關EUS工作流程的證據,包括診斷率、不利事件、手術時間、再次干預率、組織量以及病理學對分子檢測的適用性。臨床差異化不應僅基於影像品質的產品聲明,而應以多中心研究、註冊資料和同儕審查的結果為依據。
本執行摘要基於系統性的市場研究途徑,結合了二手資料研究、臨床指南審查、監管資訊和產業檢驗。主要參考資料包括世界衛生組織/國際癌症研究機構的癌症負擔數據、美國食品藥品監督管理局等公共監管資料庫、同行評審的胃腸病學文獻、美國胃腸內視鏡學會(ASGE)和歐洲胃腸內視鏡學會(ESGE)等學術協會的指南、醫院採購趨勢、醫療保健系統政策文件以及與醫療設備法規和臨床應用相關的公開資訊。
內視鏡超音波正逐漸成為精準胃腸醫學的核心技術,使影像診斷、分期、組織取樣和微創治療更接近診斷階段。推動其應用的因素包括癌症負擔的加重、對更快診斷途徑的需求、切片檢查技術的進步以及胰腺、膽道和胃腸道疾病介入治療適應症的不斷擴大。
The Endoscopy Ultrasound Market is projected to grow by USD 2.08 billion at a CAGR of 8.01% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.21 billion |
| Estimated Year [2026] | USD 1.31 billion |
| Forecast Year [2032] | USD 2.08 billion |
| CAGR (%) | 8.01% |
Endoscopy ultrasound, commonly known as endoscopic ultrasound or EUS, combines high-frequency ultrasound imaging with endoscopic visualization to assess gastrointestinal and pancreatobiliary disease from inside the digestive tract. Its clinical value is strongest where cross-sectional imaging has limitations, including pancreatic lesion characterization, subepithelial tumor evaluation, bile duct assessment, mediastinal staging, and tissue acquisition through EUS-guided fine-needle aspiration and fine-needle biopsy.
Demand is supported by the global burden of digestive cancers and complex hepatopancreatobiliary disorders. WHO/IARC GLOBOCAN 2022 estimated 20.0 million new cancer cases and 9.7 million cancer deaths globally, with colorectal, stomach, liver, esophageal, and pancreatic cancers representing major indications connected to advanced endoscopic imaging and staging workflows. In this environment, EUS is moving from a specialist diagnostic tool toward an integrated platform for diagnosis, staging, drainage, and minimally invasive intervention.
The EUS landscape is shifting from diagnostic visualization to image-guided intervention. Linear echoendoscopes, improved ultrasound processors, elastography, contrast-enhanced EUS, and dedicated biopsy needles are enabling more confident lesion assessment and higher-yield sampling, while interventional EUS is expanding the role of endoscopy suites in biliary drainage, pancreatic fluid collection management, and gallbladder drainage for selected patients.
Hospital systems are also prioritizing technologies that shorten care pathways. EUS can reduce diagnostic uncertainty by combining real-time imaging with tissue acquisition in one session, which is important for oncology care pathways that depend on rapid staging and molecular testing. Procurement decisions increasingly consider total episode-of-care value, training requirements, service contracts, scope reprocessing capacity, infection prevention, and compatibility with existing endoscopy, ultrasound, pathology, and electronic reporting infrastructure.
Artificial intelligence is beginning to influence endoscopy ultrasound through image interpretation, workflow optimization, quality management, and decision support. The strongest commercial evidence in gastrointestinal endoscopy is currently in AI-assisted colonoscopy for polyp detection, with FDA-cleared and CE-marked computer-aided detection systems demonstrating that AI can be deployed in live endoscopy workflows. EUS is following a more specialized path because image quality, operator technique, lesion heterogeneity, and limited labeled datasets create higher validation barriers.
In EUS, AI research is concentrated on pancreatic cancer differentiation, chronic pancreatitis assessment, subepithelial lesion classification, lymph node characterization, anatomical landmark recognition, and needle-guidance support. The cumulative impact will be greatest where AI improves standardization across operators, reduces missed lesions, supports trainees, and creates structured data for multidisciplinary oncology teams. Adoption will depend on prospective validation, cybersecurity, regulatory clearance, explainable outputs, and integration with electronic health records, picture archiving systems, endoscopy reporting platforms, and hospital data-governance frameworks.
Asia-Pacific is a high-growth EUS region because of large patient populations, rising cancer screening capacity, expanding tertiary hospitals, and strong demand in China, Japan, South Korea, India, Australia, and ASEAN markets. Japan and South Korea have mature endoscopy ecosystems and deep clinical expertise in upper gastrointestinal and pancreatobiliary procedures, while China and India are expanding access through hospital infrastructure investment, specialist training, and growing oncology referral networks. Australia supports adoption through concentrated advanced endoscopy centers, high clinical governance standards, and established pathways for complex gastrointestinal care.
North America remains a premium EUS market supported by advanced academic centers, complex procedural reimbursement environments, FDA-regulated technology adoption, and extensive use of EUS in pancreaticobiliary and oncology pathways. Europe benefits from guideline-driven practice, cross-border clinical research, structured public procurement, and strong adoption in Germany, France, Italy, Spain, and the United Kingdom. Latin America, the Middle East, and Africa show selective but meaningful growth led by private hospitals, cancer center development, referral-based advanced endoscopy services, and modernization programs in Brazil, Mexico, GCC states, South Africa, and major urban healthcare hubs.
ASEAN demand is shaped by private hospital investment, medical tourism, rising digestive disease diagnosis, and expanding specialist capacity in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is advancing EUS adoption through specialty hospital expansion, government healthcare modernization, and demand for minimally invasive oncology and hepatopancreatobiliary services, particularly in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait, where tertiary care investment supports advanced diagnostic and therapeutic endoscopy.
The European Union provides a large regulated EUS market where MDR compliance, clinical evidence, traceability, and procurement transparency influence supplier selection. BRICS markets combine scale with uneven access, making local distribution, clinician training, service responsiveness, and affordability critical in Brazil, Russia, India, China, and South Africa. G7 countries represent high-value innovation markets with mature reimbursement structures, academic research networks, and early adoption of validated digital technologies, while NATO member markets show overlapping demand in Europe and North America for resilient medical technology supply chains, cybersecurity, standardized quality systems, and continuity of critical healthcare equipment access.
The United States leads high-acuity EUS use through academic medical centers, ambulatory endoscopy networks, pancreatic cancer programs, and advanced therapeutic endoscopy services, while Canada emphasizes evidence-based adoption across provincial health systems and structured referral pathways. Mexico and Brazil are the largest Latin American opportunities, supported by private healthcare expansion, specialist referral centers, and demand for advanced diagnostic services in major metropolitan areas.
In Europe, the United Kingdom, Germany, France, Italy, and Spain demonstrate strong procedural expertise, guideline-led adoption, and demand for high-quality biopsy and interventional platforms, while Russia's opportunity is influenced by regional hospital modernization, procurement access, and specialist availability. China, India, Japan, Australia, and South Korea anchor Asia-Pacific: Japan and South Korea are technology-forward endoscopy markets with strong clinical proficiency, China is scaling tertiary capacity and oncology infrastructure, India is expanding specialist access across metropolitan hospital networks, and Australia combines high clinical standards with concentrated advanced endoscopy centers and multidisciplinary cancer care pathways.
Industry leaders should prioritize evidence generation in real-world EUS workflows, including diagnostic yield, adverse events, procedure time, reintervention rates, tissue adequacy, and pathology suitability for molecular testing. Clinical differentiation should be supported by multicenter studies, registry evidence, and peer-reviewed outcomes rather than product claims based only on image quality.
Manufacturers and providers should invest in training programs, simulation, proctoring, and standardized reporting because operator skill remains a major determinant of EUS outcomes. Commercial teams should align product portfolios with service support, scope uptime, infection prevention, needle compatibility, reprocessing capacity, and AI-readiness. Organizations entering emerging markets should pair distribution with clinician education, maintenance capability, and local workflow adaptation to reduce adoption friction and improve long-term utilization.
This executive summary is built from a structured market-research approach combining secondary evidence, clinical guideline review, regulatory intelligence, and industry triangulation. Key reference inputs include WHO/IARC cancer burden data, public regulatory databases such as the U.S. FDA, peer-reviewed gastroenterology literature, society guidance from organizations such as ASGE and ESGE, hospital procurement signals, health-system policy documents, and public disclosures related to device regulation and clinical adoption.
The analysis emphasizes cross-validation across demand indicators, installed-base considerations, technology maturity, reimbursement environments, clinical guidelines, regulatory pathways, and regional healthcare infrastructure. Insights are interpreted through clinical, commercial, regulatory, and operational lenses to avoid overreliance on a single data source or unverified market narrative, while excluding market estimation, market sizing, market share, and forecasting assumptions.
Endoscopy ultrasound is becoming a core technology in precision gastrointestinal care because it brings imaging, staging, tissue acquisition, and minimally invasive therapy closer to the point of diagnosis. Adoption is supported by cancer burden, demand for faster diagnostic pathways, improved biopsy technologies, and expanding interventional applications in pancreatobiliary and gastrointestinal disease management.
The next competitive phase will be defined by clinical evidence, AI-enabled standardization, workflow integration, infection prevention, training depth, and regional execution. Organizations that combine advanced EUS imaging platforms with service reliability, physician education, validated digital intelligence, and strong operational support will be best positioned in the evolving endoscopy ultrasound market.